From Simple English Wikipedia, the free encyclopedia

BioNTech SE
Company typePublic (SE)
Founded2008; 16 years ago (2008)
Number of locations
8 (2022)
Area served
Key people
RevenueDecrease 17.3 billion (2022)
Decrease €12.6 billion (2022)
Decrease €9.43 billion (2022)
Total assetsIncrease €23.3 billion (2022)
Total equityIncrease €20.1 billion (2022)
Number of employees
Increase 4,530 (2022)
Footnotes / references
Biontech FY 2022 report[1]

BioNTech SE (ˈbaɪɒnˌtek) is a German biotechnology company dedicated to the creation of active immunotherapies for treatments of serious diseases.

BioNTech headquarters in An der Goldgrube street, Mainz

It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases.[2] In 2020, the company started developing the BNT162b2 vaccine against SARS-CoV-2 with Pfizer[3] and Fosun.[4][5] In late 2020 BioNTech successfully developed, together with Pfizer, the RNA vaccine called BNT162b2 against COVID-19. The company said, it's vaccine efficacy was 95%. On 2 December 2020, the United Kingdom government gave permission to use BNT162b2 vaccinations in the country.[6] Later in December 2020 USA,[7] Canada[8] and the EU[9] also gave permission to use the BioNTech vaccine.

References[change | change source]

  1. "BioNTech 2022 Annual Report (Form 20-F)". U.S. Securities and Exchange Commission. 27 March 2023. Retrieved 24 June 2023.
  2. Form F-1 BioNTech SE (Report). U.S. Securities and Exchange Commission. 9 September 2019. Archived from the original on 14 February 2021. Retrieved 13 October 2019.
  3. Lovelace Jr., Berkeley (27 July 2020). "Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday". CNBC. Retrieved 2 August 2020.
  4. "BioNTech in China alliance with Fosun over coronavirus vaccine candidate". Reuters. Frankfurt. 15 March 2020. Retrieved 2 August 2020.
  5. Burger, Ludwig (22 April 2020). "Germany approves trials of COVID-19 vaccine candidate". Reuters. Berlin. Retrieved 2 August 2020.
  6. "UK medicines regulator gives approval for first UK COVID-19 vaccine". GOV.UK. 2 December 2020. Retrieved 25 January 2021.
  7. Commissioner, Office of the (7 January 2021). "Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions". FDA.
  8. Canada, Health (9 December 2020). "Pfizer-BioNTech COVID-19 vaccine: What you should know". aem. Retrieved 25 January 2021.
  9. "Commission approves BioNTech/Pfizer vaccine". POLITICO. 21 December 2020. Retrieved 25 January 2021.